KEGG   DRUG: Letrozole
Entry
D00964                      Drug                                   
Name
Letrozole (JAN/USP/INN);
Femara (TN)
Product
FEMARA (Novartis Pharmaceuticals Corporation)
  Generic
LETROZOLE (A-S Medication Solutions), LETROZOLE (Accord Healthcare), LETROZOLE (Aurobindo Pharma Limited), LETROZOLE (AvKARE), LETROZOLE (AvPAK), LETROZOLE (Avet Pharmaceuticals), LETROZOLE (Breckenridge Pharmaceutical), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Bryant Ranch Prepack), LETROZOLE (Chartwell RX), LETROZOLE (Dr. Reddy's Laboratories Limited), LETROZOLE (Natco Pharma Limited), LETROZOLE (NuCare Pharmaceuticals), LETROZOLE (NuCare Pharmaceuticals), LETROZOLE (Proficient Rx LP), LETROZOLE (Teva Pharmaceuticals USA), LETROZOLE (Yiling Pharmaceutical)
Formula
C17H11N5
Exact mass
285.1014
Mol weight
285.30
Structure
Simcomp
Class
Antineoplastic
 DG01596  Aromatase inhibitor
 DG01524  Triazole antineoplastic
Metabolizing enzyme substrate
 DG01638  CYP2A6 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01525  CYP2A6 inhibitor
Remark
Same as: C08163
Therapeutic category: 2529 4291
ATC code: L02BG04
Product: D00964<JP/US>
Product (mixture): D11068<US>
Efficacy
Antineoplastic, Estrogen biosynthesis inhibitor
  Disease
Breast cancer, postmenopausal (HR-positive) [DS:H00031]
Comment
Aromatase inhibitor
Target
CYP19A1 (ARO) [HSA:1588] [KO:K07434]
  Pathway
hsa00140  Steroid hormone biosynthesis
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP2A6 [HSA:1548]
Interaction
CYP inhibition: CYP2A6 [HSA:1548]
Structure map
map07043  Antineoplastics - hormones
Other map
map01522  Endocrine resistance
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L02 ENDOCRINE THERAPY
   L02B HORMONE ANTAGONISTS AND RELATED AGENTS
    L02BG Aromatase inhibitors
     L02BG04 Letrozole
      D00964  Letrozole (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Aromatase Inhibitors
   Letrozole
    D00964  Letrozole (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  25  Urogenital and anal organ agents
   252  Genital organ agents
    2529  Others
     D00964  Letrozole (JAN/USP/INN)
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D00964  Letrozole (JAN/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00964  Letrozole
  DG01524  Triazole antineoplastic
   D00964  Letrozole
 Metabolizing enzyme substrate
  DG01638  CYP2A6 substrate
   D00964  Letrozole
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D00964  Letrozole
 Metabolizing enzyme inhibitor
  DG01525  CYP2A6 inhibitor
   D00964  Letrozole
Drug classes [BR:br08332]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00964  Letrozole
Target-based classification of drugs [BR:br08310]
 Enzymes
  Oxidoreductases (EC1)
   Cytochrome P450
    CYP19A1 (ARO)
     D00964  Letrozole (JAN/USP/INN) <JP/US>
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D00964
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D00964
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D00964
Other DBs
CAS: 112809-51-5
PubChem: 7848027
ChEBI: 6413
LigandBox: D00964
NIKKAJI: J390.644B
LinkDB
KCF data

ATOM        22
            1   C1c C    25.6900  -19.1281
            2   C8y C    26.8966  -19.8333
            3   C8y C    24.4834  -19.8276
            4   N4y N    25.6957  -17.7232
            5   C8x C    26.8907  -21.2381
            6   C8x C    28.1149  -19.1338
            7   C8x C    24.4834  -21.2266
            8   C8x C    23.2710  -19.1222
            9   C8x C    24.5650  -16.9072
            10  N5x N    26.8326  -16.9072
            11  C8x C    28.1033  -21.9376
            12  C8x C    29.3273  -19.8450
            13  C8x C    23.2710  -21.9259
            14  C8x C    22.0527  -19.8276
            15  N5x N    25.0022  -15.5723
            16  C8x C    26.4069  -15.5723
            17  C8y C    29.3216  -21.2498
            18  C8y C    22.0527  -21.2266
            19  C3b C    30.5165  -21.9435
            20  C3b C    20.8402  -21.9202
            21  N3a N    31.7172  -22.6371
            22  N3a N    19.6394  -22.6430
BOND        24
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 2
            5     2   6 1
            6     3   7 2
            7     3   8 1
            8     4   9 1
            9     4  10 1
            10    5  11 1
            11    6  12 2
            12    7  13 1
            13    8  14 2
            14    9  15 2
            15   10  16 2
            16   11  17 2
            17   13  18 2
            18   17  19 1
            19   18  20 1
            20   19  21 3
            21   20  22 3
            22   12  17 1
            23   14  18 1
            24   15  16 1

» Japanese version   » Back

KEGG   DRUG: Anastrozole
Entry
D00960                      Drug                                   
Name
Anastrozole (JP18/USP/INN);
Arimidex (TN)
Product
ARIMIDEX (ANI Pharmaceuticals)
  Generic
ANASTROZOLE (A-S Medication Solutions), ANASTROZOLE (A-S Medication Solutions), ANASTROZOLE (Accord Healthcare), ANASTROZOLE (American Health Packaging), ANASTROZOLE (Asclemed USA), ANASTROZOLE (Aurobindo Pharma Limited), ANASTROZOLE (AvKARE), ANASTROZOLE (AvKARE), ANASTROZOLE (AvPAK), ANASTROZOLE (Avet Pharmaceuticals), ANASTROZOLE (BluePoint Laboratories), ANASTROZOLE (Breckenridge Pharmaceutical), ANASTROZOLE (Bryant Ranch Prepack), ANASTROZOLE (Bryant Ranch Prepack), ANASTROZOLE (Chartwell RX), ANASTROZOLE (Direct_Rx), ANASTROZOLE (Major Pharmaceuticals), ANASTROZOLE (Natco Pharma Limited), ANASTROZOLE (NuCare Pharmaceuticals), ANASTROZOLE (NuCare Pharmaceuticals), ANASTROZOLE (NuCare Pharmaceuticals), ANASTROZOLE (NuCare Pharmaceuticals), ANASTROZOLE (PD-Rx Pharmaceuticals), ANASTROZOLE (PD-Rx Pharmaceuticals), ANASTROZOLE (PD-Rx Pharmaceuticals), ANASTROZOLE (Proficient Rx LP), ANASTROZOLE (Teva Pharmaceuticals USA), ANASTROZOLE (Yiling Pharmaceutical), ANASTROZOLE (Zydus Lifesciences Limited), ANASTROZOLE (Zydus Pharmaceuticals USA)
Formula
C17H19N5
Exact mass
293.1640
Mol weight
293.37
Structure
Simcomp
Class
Antineoplastic
 DG01596  Aromatase inhibitor
 DG01524  Triazole antineoplastic
Metabolizing enzyme inhibitor
 DG01634  CYP1A2 inhibitor
 DG01643  CYP2C9 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
  DG01522  CYP3A4 inhibitor
Remark
Same as: C08159
Therapeutic category: 4291
ATC code: L02BG03
Product: D00960<JP/US>
Efficacy
Antineoplastic, Estrogen biosynthesis inhibitor
  Disease
Breast cancer, postmenopausal (HR-positive or HR-unknown) [DS:H00031]
Comment
Aromatase inhibitor
Target
CYP19A1 (ARO) [HSA:1588] [KO:K07434]
  Pathway
hsa00140  Steroid hormone biosynthesis
Interaction
CYP inhibition: CYP1A2 [HSA:1544], CYP2C9 [HSA:1559], CYP3A4 [HSA:1576]
Structure map
map07043  Antineoplastics - hormones
Other map
map01522  Endocrine resistance
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L02 ENDOCRINE THERAPY
   L02B HORMONE ANTAGONISTS AND RELATED AGENTS
    L02BG Aromatase inhibitors
     L02BG03 Anastrozole
      D00960  Anastrozole (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Aromatase Inhibitors
   Anastrozole
    D00960  Anastrozole (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D00960  Anastrozole (JP18/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00960  Anastrozole
  DG01524  Triazole antineoplastic
   D00960  Anastrozole
 Metabolizing enzyme inhibitor
  DG01634  CYP1A2 inhibitor
   D00960  Anastrozole
  DG01643  CYP2C9 inhibitor
   D00960  Anastrozole
  DG02852  CYP3A/CYP3A4 inhibitor
   DG01522  CYP3A4 inhibitor
    D00960  Anastrozole
Drug classes [BR:br08332]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00960  Anastrozole
Target-based classification of drugs [BR:br08310]
 Enzymes
  Oxidoreductases (EC1)
   Cytochrome P450
    CYP19A1 (ARO)
     D00960  Anastrozole (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D00960  Anastrozole
  D00960  Anastrozole tablets
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D00960
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D00960
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D00960
Other DBs
CAS: 120511-73-1
PubChem: 7848023
ChEBI: 2704
LigandBox: D00960
NIKKAJI: J592.428F
LinkDB
KCF data

ATOM        22
            1   C8x C     8.8900  -10.7800
            2   C8y C     8.8900  -12.1800
            3   C8x C    10.1024  -12.8800
            4   C8y C    11.3149  -12.1800
            5   C8x C    11.3149  -10.7800
            6   C8y C    10.1024  -10.0800
            7   C1b C    10.1024   -8.6802
            8   N4y N    11.2980   -7.9898
            9   C1d C     7.6776  -12.8800
            10  C1d C    12.5460  -12.8910
            11  C3b C    13.7584  -13.5910
            12  C1a C    11.8467  -14.1019
            13  C1a C    13.2468  -11.6774
            14  N3a N    14.9709  -14.2910
            15  C3b C     6.4651  -13.5800
            16  C1a C     6.9834  -11.6773
            17  C1a C     8.3830  -14.1021
            18  N3a N     5.2527  -14.2800
            19  N5x N    12.6279   -8.4272
            20  C8x C    13.4536   -7.2966
            21  N5x N    12.6335   -6.1620
            22  C8x C    11.3009   -6.5913
BOND        23
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     6   7 1
            8     7   8 1
            9     2   9 1
            10    4  10 1
            11   10  11 1
            12   10  12 1
            13   10  13 1
            14   11  14 3
            15    9  15 1
            16    9  16 1
            17    9  17 1
            18   15  18 3
            19    8  19 1
            20   19  20 2
            21   20  21 1
            22   21  22 2
            23    8  22 1

» Japanese version   » Back

KEGG   DRUG: Exemestane
Entry
D00963                      Drug                                   
Name
Exemestane (JAN/USP/INN);
Aromasin (TN)
Product
AROMASIN (Pharmacia & Upjohn Company LLC)
  Generic
EXEMESTANE (Amneal Pharmaceuticals LLC), EXEMESTANE (Aurobindo Pharma Limited), EXEMESTANE (Breckenridge Pharmaceutical), EXEMESTANE (Bryant Ranch Prepack), EXEMESTANE (Cipla USA), EXEMESTANE (Eirgen Pharma), EXEMESTANE (Florida Pharmaceutical Products), EXEMESTANE (Greenstone LLC), EXEMESTANE (Hikma Pharmaceuticals USA), EXEMESTANE (Upsher-Smith Laboratories), EXEMESTANE (Zydus Lifesciences Limited), EXEMESTANE (Zydus Pharmaceuticals USA)
Formula
C20H24O2
Exact mass
296.1776
Mol weight
296.40
Structure
Simcomp
Class
Antineoplastic
 DG01596  Aromatase inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Same as: C08162
Therapeutic category: 4291
ATC code: L02BG06
Product: D00963<JP/US>
Efficacy
Antineoplastic, Estrogen biosynthesis inhibitor
  Disease
Breast cancer, postmenopausal (ER-positive) [DS:H00031]
Comment
Aromatase inhibitor
Target
CYP19A1 (ARO) [HSA:1588] [KO:K07434]
  Pathway
hsa00140  Steroid hormone biosynthesis
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Structure map
map07043  Antineoplastics - hormones
Other map
map01522  Endocrine resistance
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L02 ENDOCRINE THERAPY
   L02B HORMONE ANTAGONISTS AND RELATED AGENTS
    L02BG Aromatase inhibitors
     L02BG06 Exemestane
      D00963  Exemestane (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Aromatase Inhibitors
   Exemestane
    D00963  Exemestane (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D00963  Exemestane (JAN/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00963  Exemestane
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D00963  Exemestane
Drug classes [BR:br08332]
 Antineoplastic
  DG01596  Aromatase inhibitor
   D00963  Exemestane
Target-based classification of drugs [BR:br08310]
 Enzymes
  Oxidoreductases (EC1)
   Cytochrome P450
    CYP19A1 (ARO)
     D00963  Exemestane (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D00963
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D00963
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D00963
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D00963
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D00963
Other DBs
CAS: 107868-30-4
PubChem: 7848026
ChEBI: 4953
PDB-CCD: EXM[PDBj]
LigandBox: D00963
NIKKAJI: J367.471A
LinkDB
KCF data

ATOM        22
            1   C2x C    12.2500  -16.2400
            2   C5x C    12.2500  -17.6400
            3   C2x C    13.4624  -18.3400
            4   C2y C    14.6749  -17.6400
            5   C1z C    14.6749  -16.2400
            6   C2x C    13.4624  -15.5400
            7   C2y C    15.8873  -18.3400
            8   C1x C    17.0997  -17.6400
            9   C1y C    17.0997  -16.2400
            10  C1y C    15.8873  -15.5400
            11  C1y C    18.3122  -15.5400
            12  C1z C    18.3122  -14.1400
            13  C1x C    17.0997  -13.4400
            14  C1x C    15.8873  -14.1400
            15  C1x C    20.7370  -15.5400
            16  C1x C    20.7370  -14.1400
            17  C5x C    19.5246  -13.4400
            18  O5x O    19.5246  -12.0400
            19  O5x O    11.0376  -18.3400
            20  C2a C    15.8873  -19.7400
            21  C1a C    14.6749  -14.8400
            22  C1a C    18.3122  -12.7400
BOND        25
            1     1   2 1
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11    5  10 1
            12    9  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 1
            16   10  14 1
            17   11  15 1
            18   15  16 1
            19   16  17 1
            20   12  17 1
            21   17  18 2
            22    2  19 2
            23    7  20 2
            24    5  21 1 #Up
            25   12  22 1 #Up

» Japanese version   » Back

DBGET integrated database retrieval system